"Malignant Pleural Mesothelioma Treatment Shows Improvement "
August 4, 2003
In phase III data, the combination of pemetrexed and cisplatin has shown a longer survival time in malignant pleural mesothelioma patients, an invasive and quickly fatal malignancy that has been linked to asbestos exposure. The patients used in the study were not eligible for curative surgery and had a 12.1 month survival time with the drug combination, compared to 9.3 months in the control group.
Mesothelioma is one of the deadliest asbestos related illnesses that have contributed to the high number of asbestos claims. Hundreds of thousands of workers were exposed to asbestos over the years and have now stepped forward with claims because of its responsible for many deaths and serious illnesses.
For more information contact us to confer with an asbestos and mesothelioma attorney.
Recent Mesothelioma Asbestos News Articles:
"Company Named in Over a Dozen Asbestos Lawsuits"
"Asbestosis Victim's Survivors Seek Justice"
"Minneapolis Residents Warned of Asbestos Dangers"
"Controversial Asbestos Screening"
"USG Continues to Suffer From Asbestos Mesothelioma Lawsuits"